Regulation of transporters by nuclear hormone receptors: Implications during inflammation

被引:53
作者
Teng, Shirley [1 ]
Piquette-Miller, Micheline [1 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 3M2, Canada
关键词
drug transporters; inflammation; cytokines; nuclear receptors; PXR;
D O I
10.1021/mp700102q
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Membrane transporters play a critical role in the absorption, distribution, and elimination of both endogenous substrates and xenobiotics. Defects in transporter function can lead to altered drug disposition including toxicity or loss of efficacy. Inflammation is one condition during which variable drug response has been demonstrated, and this can be attributed, at least in part, to changes in the expression of transporter genes. Thus, knowledge of the mechanisms behind transporter regulation can significantly contribute to our ability to predict variations in drug disposition among individuals and during inflammatory disease. The discovery of several xenobiotic-activated nuclear hormone receptors during the past decade including the pregnane X receptor, constitutive androstane receptor, and farnesoid X receptor has contributed greatly toward this endeavor. These receptors regulate the expression of transporters such as P-glycoprotein, MRP2, MRP3, BCRP, and OATP2 (Oatp1a1/OATP1B1), all of which undergo altered expression during an inflammatory response. Nuclear receptors may therefore play an important role in mediating this effect. This review presents what is currently known about the role of nuclear receptors in transporter regulation during inflammation. The use of this knowledge toward understanding interindividual variation in drug response and drug interactions during inflammation as well toward the development of therapeutics to treat transporter-related diseases will also be discussed.
引用
收藏
页码:67 / 76
页数:10
相关论文
共 103 条
[41]  
Jang SH, 2001, J PHARMACOL EXP THER, V298, P1236
[42]   Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes [J].
Jigorel, Emilie ;
Le Vee, Marc ;
Boursier-Neyret, Claire ;
Parmentier, Yannick ;
Fardel, Olivier .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (10) :1756-1763
[43]   Pregnane X receptor is a target of farnesoid X receptor [J].
Jung, Diana ;
Mangelsdorf, David J. ;
Meyer, Urs A. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (28) :19081-19091
[44]   Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats [J].
Kalitsky-Szirtes, J ;
Shayeganpour, A ;
Brocks, DR ;
Piquette-Miller, M .
DRUG METABOLISM AND DISPOSITION, 2004, 32 (01) :20-27
[45]   Role of the hepatocyte nuclear factor 4α in control of the pregnane X receptor during fetal liver development [J].
Kamiya, A ;
Inoue, Y ;
Gonzalez, FJ .
HEPATOLOGY, 2003, 37 (06) :1375-1384
[46]  
Kartenbeck J, 1996, HEPATOLOGY, V23, P1061
[47]   Regulation of multidrug resistance-associated protein 2 (ABCC2) by nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor [J].
Kast, HR ;
Goodwin, B ;
Tarr, PT ;
Jones, SA ;
Anisfeld, AM ;
Stoltz, CM ;
Tontonoz, P ;
Kliewer, S ;
Willson, TM ;
Edwards, PA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (04) :2908-2915
[48]   Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression [J].
Kauffmann, HM ;
Pfannschmidt, S ;
Zöller, H ;
Benz, A ;
Vorderstemann, B ;
Webster, JI ;
Schrenk, D .
TOXICOLOGY, 2002, 171 (2-3) :137-146
[49]   Repression of farnesoid X receptor during the acute phase response [J].
Kim, MS ;
Shigenaga, J ;
Moser, A ;
Feingold, K ;
Grunfeld, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (11) :8988-8995
[50]   Peroxisome proliferator-activated receptor α (PPARα)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice [J].
Kok, T ;
Bloks, VW ;
Wolters, H ;
Havinga, R ;
Jansen, PLM ;
Staels, B ;
Kuipers, F .
BIOCHEMICAL JOURNAL, 2003, 369 :539-547